摘要
目的探讨美沙拉嗪联合双歧杆菌三联活菌治疗溃疡性结肠炎（UC）的临床疗效。方法回顾性分析UC患者72例的临床资料，按治疗方法不同分为观察组36例、对照组36例。对照组口服美沙拉嗪治疗，观察组在口服美沙拉嗪基础上联合双歧杆菌三联活菌治疗。观察两组治疗前后血清超氧化物歧化酶（SOD）、丙二醛（MDA）及C反应蛋白（CRP）水平的变化，比较两组临床症状改善情况。结果治疗前，两组MDA、SOD、CRP水平及腹痛、腹泻、黏液血便发生情况差异均无统计学意义。治疗后，观察组MDA、SOD、CRP分别为（6．01±0．58）nmol／mL、（1．53±0．56）U／mL、（5．07±0．98）mg／L，对照组分别为（6．53±0．66）nmol／mL、（1．53±0．56）U／mL、（6．03±2．54）mg／L，两组差异均有统计学意义（t=4．550、8．054、5．115，均P〈0．05）；观察组腹泻、腹痛、黏液血便发生率分别为0．00％、2．78％、2．78％，对照组分别为11．11％、16．67％、16．67％，两组差异均有统计学意义（X2=6．235、6．956、7．956，均P〈0．05）。结论美沙拉嗪联合双歧杆菌三联活菌治疗UC，可明显能降低MDA、CRP浓度，增高SOD活性，改善临床症状，效果优于单一内服美沙拉嗪。
Objective To explore the clinical effect of mesalazine combined with bifidobactefia in the treatment of ulcerative colitis （UC）. Methods The clinical data of 72 patients with UC were retrospectively analyzed. The patients were divided into the observation group （n = 36） and control group （n = 36） according to different treatment. The .control group was given mesalazine, the observation group received mesalazine combined with bifidobacteria. The serum levels of superoxide dismutase （ SOD ）, malondialdehyde （ MDA ） and C - reactive protein （CRP） were detected. The improvement of symptoms, clinical efficacy and adverse reactions were observed. Results Before treatment,the levels of MDA, SOD, CRP and the incidence of abdominal pain, diarrhea, mucus and blood stool between the two groups had no statistically significant differences. After treatment,the levels of MDA ,SOD and CRP in the observation group were （6.01 ± 0.58） nmol/mL, （ 1.53 ± 0.56） U/mL, （5.07 ± 0. 98 ） mg/L, respectively, which in the control group were （6.53 ± 0.66 ） nmol/mL, （ 1.53 ± 0.56） U/mL, （ 6.03 ± 2.54） rag/L, respectively, there were statistically significant differences between the two groups （ t = 4. 550, 8. 054, 5. 115, all P 〈 0. 05 ）. The incidence rates of diarrhea, abdominal pain, bloody mucus in the observation group were 0.00% , 2.78% , 2.78%, respectively, which in the control group were 11.11%, 16.67 % and 16.67 %, respectively, there were statistically significant differences between the two groups （ X2 = 6. 235,6. 956,7. 956, all P 〈 0.05 ）. Conclusion Mesalazine combined with bifidobacteria in the treatment of UC can obviously reduce MDA, CRP levels, increase SOD activity, improve clinical symptoms, and its effect is better than mesalazine alone.
作者
乐琴琴
Yue Qinqin(Department of Gastroenterology, the People＇s Hospital of Cixi, Cixi, Zhejiang 315300, China)
出处
《中国基层医药》
CAS
2018年第10期1249-1252,共4页
Chinese Journal of Primary Medicine and Pharmacy
基金
浙江省温州市科技计划项目（2014Y0339）
关键词
美沙拉嗪
结肠炎
溃疡性
超氧化物歧化酶
丙二醛
Bifidobacterium
Colitis
ulcerative
Superoxide dismutase
Malondialdehyde
